Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study

Abstract

Summary Background Despite concerns that patients with liver transplants might be at increased risk of adverse outcomes from COVID-19 because of coexisting comorbidities and use of immunosuppressants, the effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on this patient group remains unclear. We aimed to assess the clinical outcomes in these patients. Methods In this multicentre cohort study, we collected data on patients with laboratory-confirmed SARS-CoV-2 infection, who were older than 18 years, who had previously received a liver transplant, and for whom data had been submitted by clinicians to one of two international registries (COVID-Hep and SECURE-Cirrhosis) at the end of the patient's disease course. Patients without a known hospitalisation status or mortality outcome were excluded. For comparison, data from a contemporaneous cohort of consecutive patients with SARS-CoV-2 infection who had not received a liver transplant were collected from the electronic patient records of the Oxford University Hospitals National Health Service Foundation Trust. We compared the cohorts with regard to several outcomes (including death, hospitalisation, intensive care unit [ICU] admission, requirement for intensive care, and need for invasive ventilation). A propensity score-matched analysis was done to test for an association between liver transplant and death. Findings Between March 25 and June 26, 2020, data were collected for 151 adult liver transplant recipients from 18 countries (median age 60 years [IQR 47–66], 102 [68%] men, 49 [32%] women) and 627 patients who had not undergone liver transplantation (median age 73 years [44–84], 329 [52%] men, 298 [48%] women). The groups did not differ with regard to the proportion of patients hospitalised (124 [82%] patients in the liver transplant cohort vs 474 [76%] in the comparison cohort, p=0·106), or who required intensive care (47 [31%] vs 185 [30%], p=0·837). However, ICU admission (43 [28%] vs 52 [8%], p<0·0001) and invasive ventilation (30 [20%] vs 32 [5%], p<0·0001) were more frequent in the liver transplant cohort. 28 (19%) patients in the liver transplant cohort died, compared with 167 (27%) in the comparison cohort (p=0·046). In the propensity score-matched analysis (adjusting for age, sex, creatinine concentration, obesity, hypertension, diabetes, and ethnicity), liver transplantation did not significantly increase the risk of death in patients with SARS-CoV-2 infection (absolute risk difference 1·4% [95% CI −7·7 to 10·4]). Multivariable logistic regression analysis showed that age (odds ratio 1·06 [95% CI 1·01 to 1·11] per 1 year increase), serum creatinine concentration (1·57 [1·05 to 2·36] per 1 mg/dL increase), and non-liver cancer (18·30 [1·96 to 170·75]) were associated with death among liver transplant recipients. Inte...

SARS-CoV-2 Seroprevalence and Clinical Features of COVID-19 in a German Liver Transplant Recipient Cohort: A Prospective Serosurvey Study

“…Early published case series in LT and solid organ transplant (SOT) recipients with coronavirus disease 2019 (COVID-19) reported a high fatality rate of up to 30%, exceeding the rate of the general population [ [1] , [2] , [3] , [4] ]. In contrast, a more recent Swiss case study and an international registry study found mortality rates comparable to those of comorbidity-matched non–transplant recipients [ 5 , 6 ]. Initial symptoms of patients with COVID-19 are diverse [ 7 ].…”

SARS-CoV-2 Virus Manifestations in the Gastrointestinal Tract: Therapeutic Implications

“…In contrast, Webb et al [ 52 ] published a study with 151 patients who received LTX. In this study, after LTX patients had no higher risk for a severe disease course.…”

SARS-CoV-2 vaccination in patients with liver disease: responding to the next big question

“…Although historically there have been anxieties that vaccination in transplant recipients may lead to the development of alloimmunity and graft rejection, no clinical evidence has emerged to support this. 12 Although liver transplant recipients have comparable rates of COVID-19-related mortality to the matched general population, 13 they do have higher rates of admission to intensive care and may have been relatively more protected throughout the pandemic due to enhanced social distancing or shielding. Therefore, we still believe this group remains a vulnerable population and should be prioritised for vaccination, with the likely benefits far outweighing the potential risks.…”